Citation Impact
Citing Papers
Epigenetic Repression of DNA Mismatch Repair by Inflammation and Hypoxia in Inflammatory Bowel Disease–Associated Colorectal Cancer
2009 StandoutNobel
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Prospective identification of tumorigenic breast cancer cells
2003 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Head and neck squamous cell carcinoma
2020 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
[1] Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5
2002
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
The hazard of accelerated tumor clonogen repopulation during radiotherapy
1988 Standout
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
Ovarian cancer
2014 Standout
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
2006 Standout
Drug penetration in solid tumours
2006 Standout
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
2001
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Lung Cancer
2008 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Head and neck cancer
2008 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer
1998 Standout
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
2006
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)
1993
Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice
1995
Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-trihydroxy-2′-butoxy)methyl-2-nitroimidazole(RP-343)
1993 StandoutNobel
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
2009
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
2009
T Cell–Mediated Elimination of B7.2 Transgenic B Cells
1997 StandoutNobel
Partial rescue of defects in Cited2-deficient embryos by HIF-1α heterozygosity
2006 StandoutNobel
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
2003
The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying Treatments
2007
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
2011 Standout
Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer
1998
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
2011 StandoutNobel
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2010 Standout
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
2001
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
First analysis on tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas
1992
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Erythropoietin increases hemoglobin in cancer patients during radiation therapy
1993
The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma
2015
Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis
2011
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
1995
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
2002
Anemia of Chronic Disease
2005 Standout
Head and Neck Cancer
2001 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck
1994
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Cancer of the Ovary
2004 Standout
Thymocyte development is normal in CTLA-4-deficient mice
1997 StandoutNobel
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Head and Neck Cancer
2020 Standout
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
Manipulation of costimulatory signals to enhance antitumor T-cell responses
1995 StandoutNobel
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
2003
A clinical phase I toxicity study of Ro 03–8799: plasma, urine, tumour and normal brain pharmacokinetics
1986
Hemoglobin, radiation, morbidity and survival
1986
Impact of β2 integrin deficiency on mouse natural killer cell development and function
2011 StandoutNobel
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
2004
Polymeric nanoparticle drug delivery technologies for oral delivery applications
2015
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Primary radiotherapy of larynx and pharynx carcinoma—An analysis of some factors influencing local control and survival
1986
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Spontaneous Skin Ulceration and Defective T Cell Function in CD18 Null Mice
1998
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
2009
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
2000
Works of E. Sandberg being referenced
Weekly Oral Idarubicin in Postmenopausal Women with Advanced Breast Cancer: A Phase II Study
1990
A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)
1993
Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial
1998
Gene Targeting for Inflammatory Cell Adhesion Molecules
1995
Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer
2006
Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study
1989
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
1996
Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.
1997
Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
1993
Misonidazole Combined with Split-Course Radiotherapy in the Treatment of Invasive Carcinoma of the Larynx and the Pharynx - A Preliminary Report of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 2
1982